好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Deep Learning Can Accurately Distinguish Between True Papilledema and Optic Disc Drusen On Ocular Fundus Photographs
Neuro-ophthalmology/Neuro-otology
P17 - Poster Session 17 (11:45 AM-12:45 PM)
2-001
To evaluate the performance of an artificial intelligence deep learning system (DLS) to automatically distinguish between true papilledema (from intracranial hypertension) and optic disc drusen (ODD) on standard ocular fundus images.

Diagnosis of papilledema requires neuro-ophthalmic expertise and expensive ancillary testing. In neurology clinics and emergency departments, its ophthalmoscopic diagnosis can be easily mistaken with pseudo-papilledema due to ODD, especially when ODDs are buried within the optic nerve head. A DLS was previously shown to accurately recognize papilledema from normal optic nerves and performed as well as expert neuro-ophthalmologists. It was also able to reliably grade the severity of papilledema.

We developed and trained a DLS using a total of 3,779 ocular fundus photographs (3,014 papilledema and 765 ODD [289 buried; 476 visible]) obtained from 1810 patients in 28 centers from 20 countries. The DLS’s performance to classify papilledema and ODD was subsequently tested on a separate dataset of 631 images obtained from 3 independent centers (424 papilledema; 207 ODD [112 buried; 95 visible]) using a receiver operating characteristic analysis. Performance metrics included the area under the receiver-operating-curve (AUC), sensitivity and specificity. The reference ophthalmologic and neurological diagnoses were established by the enrolling expert neuro-ophthalmologists, using state-of-the-art diagnostic methods.

The DLS showed high accuracy for distinguishing papilledema from ODD with an AUC of 0.98 (95%CI: 0.97-0.98), a sensitivity of 87.4% (84.1%-91.1%), and a specificity of 94.1% (92.5%-95.9%). The DLS’s performance remained excellent for distinguishing papilledema from buried ODD with a marginally reduced AUC of 0.96 (0.95-0.98).
Our trained DLS was able to reliably distinguish between life- or vision-threatening papilledema due to intracranial hypertension and the resembling, however benign, ODD. The implementation of such a DLS into a neurology clinic or emergency department could facilitate the diagnosis of patients with suspected papilledema and avoid unnecessary workup in those with ODD.
Authors/Disclosures
Valerie Biousse, MD
PRESENTER
Dr. Biousse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gensights Biologic. Dr. Biousse has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Topcon. Dr. Biousse has received publishing royalties from a publication relating to health care. Dr. Biousse has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
J. A. Fraser, MD Dr. Fraser has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Fiona E. Costello, MD (Fiona Costello Professional Corporation) Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.
No disclosure on file
Nancy J. Newman, MD, FAAN (Emory University School of Medicine) Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phelcom. The institution of Dr. Newman has received research support from GenSight. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.
Dan Milea, MD, PhD (SERI) The institution of Prof. Milea has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Optomed. The institution of Prof. Milea has received research support from NMRC Singapore.